Associations - Imfinzi (durvalumab)

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B

Imfinzi (durvalumab)

Associations
(199)

Associations
(199)

Imfinzi (durvalumab)

Associations(199)

Associations(199)

Associations
(199)

Associations
(199)